RxDoctor Payments Data

Carlos Matos, MD

Internal Medicine · Santurce, PRNPI 1912989609

Payments from drug & device makers

$3,564in general payments, 2019–2025

Across 56 payments — averaging $63.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$774
  • Atricure, Inc.$489
  • Johnson & Johnson$485
  • Medtronic$375
  • AstraZeneca$326
  • Boston Scientific$299
  • plus $815 from 8 others

What the payments were for

  • Speaking & faculty fees$2006%
  • Travel & lodging$48914%
  • Food & beverage$2,87681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,564 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$12,606
Medicare patients
62
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol113$109,516
JanumetSitagliptin Phos/Metformin Hcl53$70,427
JardianceEmpagliflozin50$67,449
SynthroidLevothyroxine Sodium371$43,028
JentaduetoLinagliptin/Metformin Hcl43$36,839
JanuviaSitagliptin Phosphate25$33,306
TrulicityDulaglutide13$31,817
XareltoRivaroxaban25$31,020
Xigduo XrDapaglifloz Propaned/Metformin35$29,786
EliquisApixaban23$25,437
TradjentaLinagliptin15$15,107
Humalog Mix 75-25Insulin Lispro Protamin/Lispro37$10,936
Atorvastatin Calcium574$7,138
Levothyroxine Sodium330$5,611
Metoprolol Succinate261$5,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto, Tradjenta$110$119,394108 claims
AstraZenecaFarxiga$326$109,516113 claims
MerckJanumet, Januvia$206$103,73378 claims
Johnson & JohnsonXarelto$485$31,02025 claims
Sanofi-aventis U.S. LLCLantus$240$4,96640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Santurce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →